NCT00222144View on ClinicalTrials.gov

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Lung Cancer
Interventions
DRUG

Gleevec and Taxotere

Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15

Trial Locations (2)

64128

VA Medical Center, Kansas City

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Kansas Masonic Cancer Research Institute

UNKNOWN

lead

University of Kansas

OTHER